157 related articles for article (PubMed ID: 36660611)
1. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
[TBL] [Abstract][Full Text] [Related]
2. Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events.
Tu L; Ye Y; Tang X; Liang Z; You Q; Zhou J; Pan Z
Front Oncol; 2021; 11():757069. PubMed ID: 35004277
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
[TBL] [Abstract][Full Text] [Related]
4. Case report: A rare case of sintilimab-induced gastric stenosis and literature review.
Song K; Dong H; Jiang S; Xu X; Zhang C; Chen Q; Wang Q
Front Oncol; 2023; 13():1091459. PubMed ID: 36761970
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.
Li H; Mu F; Zou B; Wang L
Medicine (Baltimore); 2023 Aug; 102(31):e34432. PubMed ID: 37543824
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature.
Liu Y; Tang J; Yu LY; Jiang Q
Explore (NY); 2023; 19(5):730-735. PubMed ID: 36878772
[TBL] [Abstract][Full Text] [Related]
9. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
10. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
Li G; Gong S; Wang N; Yao X
Front Immunol; 2022; 13():989966. PubMed ID: 36090976
[TBL] [Abstract][Full Text] [Related]
11. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
Ai Q; Chen W; Li Y; Li G
Front Immunol; 2022; 13():840916. PubMed ID: 35720298
[TBL] [Abstract][Full Text] [Related]
12. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
Bi H; Ren D; Wang Q; Ding X; Wang H
Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
[TBL] [Abstract][Full Text] [Related]
14. Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review.
Zhou S; Zhang Z; Feng X; Zhao C; Jiang L
Front Pharmacol; 2023; 14():1276788. PubMed ID: 38161699
[TBL] [Abstract][Full Text] [Related]
15. A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma.
Zheng S; Zhang H; Hu B; Zhou J; Wen L; Li M
Heliyon; 2023 Jun; 9(6):e16874. PubMed ID: 37342584
[TBL] [Abstract][Full Text] [Related]
16. Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma.
Li X; Li G; Chen D; Su L; Wang RP; Zhou Y
Front Oncol; 2023; 13():912168. PubMed ID: 37781182
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.
Wu JY; Kang K; Yi J; Yang B
World J Clin Cases; 2022 Jun; 10(18):6110-6118. PubMed ID: 35949835
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.
Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H
Front Oncol; 2022; 12():1065137. PubMed ID: 36620577
[TBL] [Abstract][Full Text] [Related]
19. PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study.
Huang G; Liu S; Dong J; Xi X; Kong R; Li W; Du Q
Front Pharmacol; 2022; 13():974376. PubMed ID: 36438818
[No Abstract] [Full Text] [Related]
20. EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report.
Zhang Z; Liu N; Li Q
Transl Cancer Res; 2022 Jun; 11(6):1829-1835. PubMed ID: 35836542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
